NASDAQ:BDSI - Nasdaq - Common Stock
We assign a fundamental rating of 3 out of 10 to BDSI. BDSI was compared to 195 industry peers in the Pharmaceuticals industry. The financial health of BDSI is average, but there are quite some concerns on its profitability. BDSI is valued quite expensive, but it does show an excellent growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 26.14% | ||
ROE | 45.18% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 22.27% | ||
PM (TTM) | 50.91% | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.29 | ||
Debt/FCF | N/A | ||
Altman-Z | 2.65 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.45 | ||
Quick Ratio | 2.17 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 6.73 | ||
Fwd PE | 15.84 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | 11.15 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
5.59
0 (-0.09%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 6.73 | ||
Fwd PE | 15.84 | ||
P/S | 3.31 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 2.94 | ||
P/tB | N/A | ||
EV/EBITDA | 11.15 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 26.14% | ||
ROE | 45.18% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | 22.27% | ||
PM (TTM) | 50.91% | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.29 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | N/A | ||
Cap/Sales | N/A | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 2.45 | ||
Quick Ratio | 2.17 | ||
Altman-Z | 2.65 |